6.8.01: Investing in the Second Biotechnology Revolution Conference Issue
Nine analysts, four money managers and top management from eleven sector firms examine the Investing in the Second Biotechnology Revolution Conference companies in this special 118-page issue from The Wall Street Transcript.

    Online subscribers to the Healthcare sector also get
    Specialty Pharmaceuticals Report & Health Care IT & Drug Distribution Issue

  1. The Biotechnology Revolution: An Overview - In an in-depth (4,100 words) Analyst Interview, Carl Feldbaum, President of the Biotechnology Industry Organization, examines the outlook for the sector and shares specific stock recommendations.
  2. Investment Opportunities in Biotechnology - Money Manager Interview, Carl Gordon, Founding General Partner of OrbiMed Advisors LLC, examines portfolio management strategies in this timely and deeply informative 3,800-word interview from The Wall Street Transcript.
  3. Biotechnology Overview - Money Manager Interview, Mary Ann Gray, Health Care Manager of Federated Kaufmann Fund, examines portfolio management strategies in this timely and deeply informative 4,300-word interview from The Wall Street Transcript.
  4. The New Biotechnology Environment - In an in-depth (3,900 words) Analyst Interview, Sushant Kumar, Newest Member Partner of Mehta Partners, examines the outlook for the sector and shares specific stock recommendations.
  5. Platform Technology Classes - In an in-depth (3,300 words) Analyst Interview, Ajay Bansal, Team Member at Mehta Partners, examines the outlook for the sector and shares specific stock recommendations.
  6. Investing in Biotechnology Funds - Money Manager Interview, Brian Younger, Portfolio Manager for Fidelity Investments, examines portfolio management strategies in this timely and deeply informative 5,200-word interview from The Wall Street Transcript.
  7. Investing in Biomedical Technology - Money Manager Interview, Michael Walsh, Founder of Kilkenny Capital Management, LLC, examines portfolio management strategies in this timely and deeply informative 5,700-word interview from The Wall Street Transcript.
  8. Biotechnology Fund Management - In an in-depth (3,600 words) Analyst Interview, Lissa Morgenthaler, Portfolio Manager of the Monterey Murphy New World Biotechnology Fund, examines the outlook for the sector and shares specific stock recommendations.
  9. Biotechnology Overview - In an in-depth (4,500 words) Analyst Interview, Franklin Berger, Vice President in the Equity Research Department at JP Morgan H&Q, examines the outlook for the sector and shares specific stock recommendations.
  10. Late-Stage Biotechnology Companies - In an in-depth (2,700 words) Analyst Interview, John Sonnier, Senior Biotechnology Analyst at Prudential Securities, examines the outlook for the sector and shares specific stock recommendations.
  11. Investing in Biotechnology - In an in-depth (3,100 words) Analyst Interview, Bill Tanner, Managing Director at SG Cowen, examines the outlook for the sector and shares specific stock recommendations.
  12. Opportunities in Biotechnology - In an in-depth (4,300 words) Analyst Interview, Carol Werther, Senior Vice President, Equity Research at Adams, Harkness & Hill, examines the outlook for the sector and shares specific stock recommendations.
  13. CEO and Sponsored interviews (average 2,500 words). Top management of eleven sector firms examine the outlook for their firm and the sector. Firms include:

    AltaRex, Bioenvision, Blau Mancino Associates, Boston Life Sciences, Curis, Deloitte & Touche, Frommer Lawrence & Haug LLP, Gold Partners, Greenberg Traurig, MPM Group, Onyx Pharmaceuticals

    14. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE